Analyst Profile

Followed by 10,154 followers
.
Jason McCarthy

Jason McCarthy

Maxim Group
Wall Street Analyst
#8,053 out of 8,141 Wall Street Analysts
#23,867 out of 24,284 experts

Success Rate

16%
72 out of 451 transactions made a profit

Average Return

-37.50%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Jason McCarthy's trades since 2015 and holding each position for 1 Year would result in 15.96% of your transactions generating a profit, with an average return of -37.5% per rating.

Stock Rating Distribution

3KRatings
87.82% Buy
11.54% Hold
0.63% Sell
Distribution of Jason McCarthy's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market
CanadaCanadian Market
United KingdomUK Market

Best Rating

Stock:
Reviva Pharmaceuticals Holdings, Inc.
(RVPH)
Rating:Buy
Date:Aug 16, 2022 - Today
Return:+472.40%
The most profitable rating made by Jason McCarthy

Jason McCarthy's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
Celyad
Dec 01, 2015
Buy
Reiterated
$100.00
(9245.79% Upside)
4Ratings
0.00%
Acer Therapeutics
Oct 28, 2016
Hold
Downgraded
12Ratings
0.00%
Savara
Apr 19, 2017
Hold
Assigned
13Ratings
0.00%
Bavarian Nordic
May 05, 2017
Buy
Reiterated
13Ratings
0.00%
Agenus
May 08, 2017
Buy
Reiterated
$7.00
(149.11% Upside)
12Ratings
0.00%
Edesa Biotech
May 10, 2017
Buy
Reiterated
$2.00
(123.19% Upside)
12Ratings
0.00%
Bio-Path Holdings
May 15, 2017
Buy
Reiterated
$20.00
(1269.86% Upside)
5Ratings
0.00%
Oncotelic Therapeutics
Aug 01, 2017
Hold
Reiterated
6Ratings
0.00%
MNTA
Momenta Pharma
Aug 03, 2017
Sell
Reiterated
12Ratings
0.00%
NovaBay Pharma
Aug 11, 2017
Hold
Reiterated
2Ratings
0.00%
List of latest recommendations made by Jason McCarthy. Click to expand and see Jason McCarthy's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >